Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Tectonic Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.6% during the 3rd ...

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the ...